COMBINED EFFECTS OF ZOLEDRONIC ACID AND SODIUM PENTABORATEPENTAHYDRATE ON PROLIFERATION, MIGRATION AND APOPTOSIS OF HUMANNEUROBLASTOMA CELL LINE

Neuroblastoma occurs in childhood with high aggressiveness and is one of the most common solid tumors. Although there are many different strategies to fight neuroblastoma including surgical treatment, chemotherapy, radiotherapy, and immunotherapy, ultimately successful treatment has not been evaluated yet. Effective, safe, and less toxic options must be investigated. Zoledronic acid (ZOL)is a type of amino-bisphosphonates and has been used in bone-related diseases for more than 20 years and the anti-tumor ability of the ZOL is known. Boron is a natural product and many regenerativeproperties of boron compounds such as myogenic, osteogenic, and odontogenic induction potential have been discovered. Besides, the boron compound also displayed anti-cancer characteristics in different studies. In the current study, we evaluated the possible synergistic effects of the ZOL and Sodium pentaborat tetrahydrate (SPT) on the neuroblastoma cells, SH-SY5Y. As a result, ZOL and SPT combination exhibited the most favorable anti-proliferative, pro-apoptotic and anti-migratory effects compared to the ZOL and SPT alone and control groups. Moreover, molecular evidence has indicated that while expression of the proliferative gene, NFκB was significantly decreased in the combination group compared to all other groups, pro-apoptotic genes, were overexpressed. To sum up, obtained results from the recent study lead it necessary to carry out more detailed studies.

PDF

___

[1] S.B. Whittle, V. Smith, E. Doherty, S. Zhao, S. McCarty, P.E. Zage, 'Overview and recent advances in the treatment of neuroblastoma', Expert Rev. Anticancer Ther., 17, 369–386, 2017.
[2] P.D.Q.P.T.E. Board, Neuroblastoma Treatment (PDQ®), in: PDQ Cancer Inf. Summ., National Cancer Institute (US), 2020.
[3] G.M. Brodeur, 'Neuroblastoma: biological insights into a clinical enigma', Nat. Rev. Cancer., 3, 203–216, 2003.https://doi.org/10.1038/nrc1014.
[4] H. Bassiri, A. Benavides, M. Haber, S.K. Gilmour, M.D. Norris, M.D. Hogarty, 'Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma', Transl. Pediatr., 4, 226, 2015.
[5] R.G.G. Russell, 'Bisphosphonates: mode of action and pharmacology', Pediatrics., 119, S150-- S162, 2007.
[6] G.I. Baroncelli, S. Bertelloni, 'The use of bisphosphonates in pediatrics', Horm. Res. Paediatr., 82, 290–302, 2014.
[7] N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, S. Takashima, 'Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial', J. Clin. Oncol., 23, 3314–3321, 2005.
[8] F. Daubiné, C. Le Gall, J. Gasser, J. Green, P. Clézardin, 'Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis', J. Natl. Cancer Inst., 99, 322–330, 2007.
[9] F.H. Nielsen, 'Update on human health effects of boron', J. Trace Elem. Med. Biol., 28, 383– 387, 2014.
[10] R. I Scorei, R. Popa, 'Boron-containing compounds as preventive and chemotherapeutic agents for cancer', Anti-Cancer Agents Med. Chem. (Formerly Curr. Med. Chem. Agents)., 10, 346– 351, 2010.
[11] S. Mahabir, M.R. Spitz, S.L. Barrera, Y.Q. Dong, C. Eastham, M.R. Forman, 'Dietary boron and hormone replacement therapy as risk factors for lung cancer in women', Am. J. Epidemiol., 167, 1070–1080, 2008.
[12] F. Xu, H.E. Goldbach, P.H. Brown, R.W. Bell, T. Fujiwara, C.D. Hunt, S. Goldberg, L. Shi, Advances in plant and animal boron nutrition, Springer, 2007.
[13] Y. Cui, M.I. Winton, Z.-F. Zhang, C. Rainey, J. Marshall, J.B. De Kernion, C.D. Eckhert, 'Dietary boron intake and prostate cancer risk', Oncol. Rep., 11, 887–892, 2004.
[14] S. Ackermann, M. Cartolano, B. Hero, A. Welte, Y. Kahlert, A. Roderwieser, C. Bartenhagen, E. Walter, J. Gecht, L. Kerschke, R. Volland, R. Menon, J.M. Heuckmann, M. Gartlgruber, S. Hartlieb, K.-O. Henrich, K. Okonechnikov, J. Altmüller, P. Nürnberg, S. Lefever, B. de Wilde, F. Sand, F. Ikram, C. Rosswog, J. Fischer, J. Theissen, F. Hertwig, A.D. Singhi, T. Simon, W. Vogel, S. Perner, B. Krug, M. Schmidt, S. Rahmann, V. Achter, U. Lang, C. Vokuhl, M. Ortmann, R. Büttner, A. Eggert, F. Speleman, R.J. OtextquoterightSullivan, R.K. Thomas, F. Berthold, J. Vandesompele, A. Schramm, F. Westermann, J.H. Schulte, M. Peifer, M. Fischer, 'A mechanistic classification of clinical phenotypes in neuroblastoma', Science (80-. )., 362, 1165–1170, 2018.https://doi.org/10.1126/science.aat6768.
[15] N.M. La-Beck, X. Liu, H. Shmeeda, C. Shudde, A.A. Gabizon, Repurposing aminobisphosphonates by liposome formulation for a new role in cancer treatment, in: Semin. Cancer Biol., 2019.
[16] A.C. Hirbe, A.J. Roelofs, D.H. Floyd, H. Deng, S.N. Becker, L.G. Lanigan, A.J. Apicelli, Z. Xu, J.L. Prior, M.C. Eagleton, others, 'The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts', Bone., 44, 908–916, 2009.
[17] V. Stresing, P.G. Fournier, A. Bellahcène, I. Benza"id, H. Mönkkönen, M. Colombel, F.H. Ebetino, V. Castronovo, P. Clézardin, 'Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase', Bone., 48, 259–266, 2011.
[18] S. Dhesy-Thind, G.G. Fletcher, P.S. Blanchette, M.J. Clemons, M.S. Dillmon, E.S. Frank, S. Gandhi, R. Gupta, M. Mates, B. Moy, others, 'Use of adjuvant bisphosphonates and other bonemodifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline', J Clin Oncol., 35, 2062–2081, 2017.
[19] P.N. Taşlı, A. Doğan, S. Demirci, F. Şahin, 'Boron Enhances Odontogenic and Osteogenic Differentiation of Human Tooth Germ Stem Cells (hTGSCs) In Vitro', Biol. Trace Elem. Res., 153, 419–427, 2013.https://doi.org/10.1007/s12011-013-9657-0.
[20] H. Apdik, A. Doğan, S. Demirci, S. Aydın, F. Şahin, 'Dose-dependent Effect of Boric Acid on Myogenic Differentiation of Human Adipose-derived Stem Cells (hADSCs)', Biol. Trace Elem. Res., 165, 123–130, 2015.https://doi.org/10.1007/s12011-015-0253-3.
[21] Q. Jiang, Q. Zhong, Q. Zhang, S. Zheng, G. Wang, 'Boron-based 4-hydroxytamoxifen bioisosteres for treatment of de novo tamoxifen resistant breast cancer', ACS Med. Chem. Lett., 3, 392–396, 2012.
[22] H. Hernández-López, G. Sánchez-Miranda, J.G. Araujo-Huitrado, A.J. Granados-López, J.A. López, S. Leyva-Ramos, L. Chacón-García, 'Synthesis of Hybrid Fluoroquinolone-Boron Complexes and Their Evaluation in Cervical Cancer Cell Lines', J. Chem., 2019, 5608652, 2019.https://doi.org/10.1155/2019/5608652.
[23] T.B. Hayal, O.K. Kırbaş, B.T. Bozkurt, P.N. Taşlı, B. Bülbül, S. Beyaz, F. Şahin, 'Lead Borate Nanoparticles Induce Apoptotic Gene Activity in P53 Mutant Cancer Cells', Biol. Trace Elem. Res., 2021.https://doi.org/10.1007/s12011-021-02696-0.
[24] E. Avsar Abdik, F. Kaleagasioglu, H. Abdik, F. Sahin, M.R. Berger, 'ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling', Anticancer. Drugs., 30, 383–393, 2019.
[25] J.-W. Hyun, G.-J. Cheon, H.-S. Kim, Y.-S. Lee, E.-Y. Choi, B.-H. Yoon, J.-S. Kim, M.-H. Chung, 'Radiation sensitivity depends on OGG1 activity status in human leukemia cell lines', Free Radic. Biol. Med., 32, 212–220, 2002.
[26] T. Ara, Y.A. DeClerck, 'Mechanisms of invasion and metastasis in human neuroblastoma', Cancer Metastasis Rev., 25, 645–657, 2006.https://doi.org/10.1007/s10555-006-9028-9.
[27] Y. Savci, O.K.K. Kirbas, B.T. Bozkurt, E.A. Abdik, P.N. Tasli, F. Sahin, H. Abdik, 'Grapefruit Derived Extracellular Vesicles as a Promising Cell-free Therapeutic Tool for Wound Healing', Food Funct., 2021.
[28] A.R. Hussain, S.O. Ahmed, M. Ahmed, O.S. Khan, S. Al AbdulMohsen, L.C. Platanias, K.S. Al-Kuraya, S. Uddin, 'Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis', PLoS One., 7, e39945, 2012.
[29] W. Li, H. Wang, C. Kuang, J. Zhu, Y. Yu, Z. Qin, J. Liu, L. Huang, 'An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro', Mol. Cell. Biochem., 363, 135–145, 2012.
[30] L. Lindenboim, D. Grozki, A.R. Amsalem-Zafran, A. Peña-Blanco, G.G. Gundersen, C. Borner, D. Hodzic, A.J. Garcia-Sáez, H.J. Worman, R. Stein, 'Apoptotic stress induces Bax-dependent, caspase-independent redistribution of LINC complex nesprins', Cell Death Discov., 6, 90, 2020.https://doi.org/10.1038/s41420-020-00327-6.
[31] L. Du, Z. Fei, S. Song, N. Wei, 'Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio', Biomed. Pharmacother., 95, 447–452, 2017. https://doi.org/https://doi.org/10.1016/j.biopha.2017.08.119.